HomepageEarnings Events Newsdesk 18 minutes ago Biogen Inc (BIIB) Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity Biogen Inc (NASDAQ: BIIB) FY 2026 Other Release Roivant Sciences (ROIV) New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis » « Incyte Corporation (INCY) Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting Newsdesk: